guest ::
| Home > Publications Database > Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies |
| Home > Publications Database > Spinocerebellar Ataxia Type 3 Pathophysiology—Implications for Translational Research and Clinical Studies |
| Journal Article (Review Article) | DZNE-2024-00359 |
; ; ; ;
2024
Molecular Diversity Preservation International
Basel
This record in other databases: 
Please use a persistent id in citations: doi:10.3390/ijms25073984
Abstract: The spinocerebellar ataxias (SCA) comprise a group of inherited neurodegenerative diseases. Machado-Joseph Disease (MJD) or spinocerebellar ataxia 3 (SCA3) is the most common autosomal dominant form, caused by the expansion of CAG repeats within the ataxin-3 (ATXN3) gene. This mutation results in the expression of an abnormal protein containing long polyglutamine (polyQ) stretches that confers a toxic gain of function and leads to misfolding and aggregation of ATXN3 in neurons. As a result of the neurodegenerative process, SCA3 patients are severely disabled and die prematurely. Several screening approaches, e.g., druggable genome-wide and drug library screenings have been performed, focussing on the reduction in stably overexpressed ATXN3(polyQ) protein and improvement in the resultant toxicity. Transgenic overexpression models of toxic ATXN3, however, missed potential modulators of endogenous ATXN3 regulation. In another approach to identify modifiers of endogenous ATXN3 expression using a CRISPR/Cas9-modified SK-N-SH wild-type cell line with a GFP-T2A-luciferase (LUC) cassette under the control of the endogenous ATXN3 promotor, four statins were identified as potential activators of expression. We here provide an overview of the high throughput screening approaches yet performed to find compounds or genomic modifiers of ATXN3(polyQ) toxicity in different SCA3 model organisms and cell lines to ameliorate and halt SCA3 progression in patients. Furthermore, the putative role of cholesterol in neurodegenerative diseases (NDDs) in general and SCA3 in particular is discussed.
Keyword(s): Humans (MeSH) ; Animals (MeSH) ; Machado-Joseph Disease: genetics (MeSH) ; Translational Research, Biomedical (MeSH) ; Spinocerebellar Ataxias: genetics (MeSH) ; Translational Science, Biomedical (MeSH) ; Animals, Genetically Modified (MeSH) ; ASO ; CRISPR/Cas ; SREBP ; cholesterol ; clinical trials ; compound modifier ; genomic modifier ; high throughput screening ; miRNA ; spinocerebellar ataxia 3 (SCA3) ; transcriptional and posttranscriptional regulation
; 
; 
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
PDF
PDF (PDFA)